Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Capital Expenditures (2021 - 2024)

Historic Capital Expenditures for SAB Biotherapeutics (SABS) over the last 4 years, with Q4 2024 value amounting to $55377.0.

  • SAB Biotherapeutics' Capital Expenditures fell 1840.0% to $55377.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $337262.0, marking a year-over-year increase of 7106.53%. This contributed to the annual value of $337262.0 for FY2024, which is 7106.53% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Capital Expenditures of $55377.0 as of Q4 2024, which was down 1840.0% from $100300.0 recorded in Q3 2024.
  • SAB Biotherapeutics' 5-year Capital Expenditures high stood at $3.5 million for Q2 2021, and its period low was $21300.0 during Q1 2023.
  • For the 4-year period, SAB Biotherapeutics' Capital Expenditures averaged around $852780.4, with its median value being $109027.0 (2022).
  • As far as peak fluctuations go, SAB Biotherapeutics' Capital Expenditures tumbled by 9843.07% in 2023, and later soared by 50598.12% in 2024.
  • SAB Biotherapeutics' Capital Expenditures (Quarter) stood at $2.4 million in 2021, then tumbled by 95.01% to $117754.0 in 2022, then plummeted by 42.37% to $67864.0 in 2023, then dropped by 18.4% to $55377.0 in 2024.
  • Its last three reported values are $55377.0 in Q4 2024, $100300.0 for Q3 2024, and $52511.0 during Q2 2024.